Search
Banoxantrone
go.drugbank.com/drugs/DB04975InvestigationalBanoxantrone is a highly selective bioreductive drug that is activated in, and is preferentially toxic to, hypoxic cells in tumours. … Banoxantrone was also efficacious in tumour models when administered in combination with either cisplatin or chemoradiation. [A3115]
Stamulumab
go.drugbank.com/drugs/DB05915InvestigationalMYO-029 is a human anti-GDF-8 monoclonal antibody, which is being developed to treat muscle-wasting diseases including muscular dystrophy and age-related sarcopenia.
Chlorphentermine
go.drugbank.com/drugs/DB01556ApprovedIllicitWithdrawnA sympathomimetic agent that was formerly used as an anorectic. It has properties similar to those of dextroamphetamine. It has been implicated in lipid storage disorders and pulmonary hypertension.
Interferon Gamma
go.drugbank.com/drugs/DB15753InvestigationalInterferon gamma is a Type 1 inflammatory cytokine and the only type II interferon. It has antitumor properties, antiviral activities, and important immunoregulatory functions. … The interferon is primarily produced by activated T lymphocytes and natural killer cells.
Synonyms: IFN-G, IFN-γIcotinib
go.drugbank.com/drugs/DB11737InvestigationalIcotinib is a potent and specific epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) Icotinib was approved in China by the SFDA in June, 2011 and in January 2014, Beta Pharma, Inc … . was given a “May Proceed” from the US FDA to conduct a Phase I study for the evaluation of icotinib as a treatment of EGFR+ Non-Small Cell Lung Cancer (NSCLC).
NNZ-2591
go.drugbank.com/drugs/DB15601InvestigationalIt was granted Orphan Drug Designation by the FDA in October 2019[L11103] and was granted a patent by the European Patent Office in December 2019. … [L11100] Clinical trials are expected to begin in 2020.[L11103,L11100]
Diodone
go.drugbank.com/drugs/DB13568ExperimentalCategories: Compounds used in a research, industrial, or household settingCNS-5161
go.drugbank.com/drugs/DB05824ExperimentalCNS 5161 is a blocker of the NMDA ion channel and has completed Phase IIa proof of concept clinical trials as a novel compound for the treatment of neuropathic pain.